Screener
Bausch Health Companies BHC Salix — Additions
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bausch Health Companies in its filing.
Tagged under the XBRL concept us-gaap:GoodwillAcquiredDuringPeriod.
The source filing: Bausch Health Companies’s 10-Q, filed April 30, 2026.
- Filed
- Apr 29, 2026, 6:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000885590-26-000053
| (in millions) | Salix | International | Solta Medical | Diversified | Bausch + Lomb | Total |
|---|---|---|---|---|---|---|
| Balance, January 1, 2025 | $3,159 | $792 | $115 | $1,759 | $5,262 | $11,087 |
| Additions | — | — | 22 | — | 97 | 119 |
| Impairment | — | — | — | (145) | — | (145) |
| Goodwill reclassified to assets held for sale | — | (4) | — | — | — | (4) |
| Foreign exchange and other | — | 109 | — | (33) | 138 | 214 |
| Balance, December 31, 2025 | 3,159 | 897 | 137 | 1,581 | 5,497 | 11,271 |
| Additions | — | — | — | — | — | — |
| Impairment | (1,426) | — | — | — | — | (1,426) |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Bausch Health Companies's salix — additions?
- Bausch Health Companies (BHC) reported salix — additions of $0 in Q1 2026.
- What does salix — additions mean?
- Captures the value of new goodwill recognized during the reporting period specifically attributable to the Salix segment, typically resulting from business combinations or acquisitions. This metric indicates the company's inorganic growth activity within its core pharmaceutical segments. It reflects capital deployed to expand the segment's market footprint or product pipeline.
Ask your AI about Bausch Health Companies's salix — additions.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude